Trevi Therapeutics (TRVI) Tops Q3 EPS by 5c

Trevi Therapeutics (NASDAQ: TRVI) reported Q3 EPS of ($0.12), $0.05 better than the analyst estimate of ($0.17).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
• Alcoa agrees to buy South32 assets for $4.1 billion
• BNP Paribas Exane Starts LEG Immobilien AG (LEG:GR) (LEGIF) at Underperform